Novacyt Stock

Novacyt Debt/EBITDA

The Total Debt to EBITDA Ratio of Novacyt (ALNOV.PA) as of Sep 5, 2026 is -1.59. In the previous year, Total Debt to EBITDA Ratio was -1.39 — a change of 14.12% (lower).

Debt/EBITDA

-1.59

YoY

14.12%

Last updated:

Total Debt to EBITDA Ratio of Novacyt is 2026 -1.59 . Total Debt to EBITDA Ratio of Novacyt was 2025 -1.39 . It decreases by 14.12% lower compared to the previous year.

The Novacyt Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-3.38 GBP
Jan 1, 2018
70.51 GBP
Jan 1, 2019
94.47 GBP
Jan 1, 2020
0.01 GBP
Jan 1, 2021
0.61 GBP
Jan 1, 2022
-0.07 GBP
Jan 1, 2023
-1.39 GBP
Jan 1, 2024
-1.59 GBP
The Novacyt Debt/EBITDA history
YEARDebt/EBITDAYoY
-1.59+14.12%
-1.39+1,810.88%
-0.07-111.87%
0.61+4,434.64%
0.01-99.99%
94.47+33.99%
70.51-2,188.68%
-3.38+68.12%
-2.01+78.78%
-1.12+297.80%
-0.28
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Total Debt to EBITDA Ratio of Novacyt is -1.59 in 2026.

Total Debt to EBITDA Ratio of Novacyt changed from -1.39 to -1.59, representing a 14.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Novacyt since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Novacyt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Novacyt

All Key Metrics — Novacyt